How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
© 2024. The Author(s)..
Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012-2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led to the registration of midostaurin, gemtuzumab ozogamicin, CPX-351, oral azacitidine, and venetoclax. Our analyses highlight important differences in real-world outcomes compared to clinical trial populations, including variations in anthracycline type, cytarabine intensity and scheduling during consolidation, and the frequency of allogeneic hematopoietic cell transplantation in first remission. Although real-world outcomes were comparable to some published studies, notable differences were apparent in others. If historical datasets were used to assess the impact of novel therapies, this work underscores the need to assess diverse datasets to enable geographic differences in treatment outcomes to be accounted for.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Blood cancer journal - 14(2024), 1 vom: 26. März, Seite 54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tiong, Ing Soo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41408-024-00996-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370214102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370214102 | ||
| 003 | DE-627 | ||
| 005 | 20240330001454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-024-00996-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM370214102 | ||
| 035 | |a (NLM)38531863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tiong, Ing Soo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012-2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led to the registration of midostaurin, gemtuzumab ozogamicin, CPX-351, oral azacitidine, and venetoclax. Our analyses highlight important differences in real-world outcomes compared to clinical trial populations, including variations in anthracycline type, cytarabine intensity and scheduling during consolidation, and the frequency of allogeneic hematopoietic cell transplantation in first remission. Although real-world outcomes were comparable to some published studies, notable differences were apparent in others. If historical datasets were used to assess the impact of novel therapies, this work underscores the need to assess diverse datasets to enable geographic differences in treatment outcomes to be accounted for | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Gemtuzumab |2 NLM | |
| 650 | 7 | |a 93NS566KF7 |2 NLM | |
| 700 | 1 | |a Wall, Meaghan |e verfasserin |4 aut | |
| 700 | 1 | |a Bajel, Ashish |e verfasserin |4 aut | |
| 700 | 1 | |a Kalro, Akash |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming, Shaun |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Andrew W |e verfasserin |4 aut | |
| 700 | 1 | |a Thiagarajah, Nisha |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Chong Chyn |e verfasserin |4 aut | |
| 700 | 1 | |a Latimer, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, David |e verfasserin |4 aut | |
| 700 | 1 | |a Marlton, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Enjeti, Anoop |e verfasserin |4 aut | |
| 700 | 1 | |a Fong, Chun Yew |e verfasserin |4 aut | |
| 700 | 1 | |a Cull, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Glen |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarer, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Kipp, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanathan, Sundra |e verfasserin |4 aut | |
| 700 | 1 | |a Verner, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Tiley, Campbell |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Hahn, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, John |e verfasserin |4 aut | |
| 700 | 1 | |a Taper, John |e verfasserin |4 aut | |
| 700 | 1 | |a Purtill, Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Warburton, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Stevenson, William |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Beligaswatte, Ashanka |e verfasserin |4 aut | |
| 700 | 1 | |a Mutsando, Howard |e verfasserin |4 aut | |
| 700 | 1 | |a Hertzberg, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Shortt, Jake |e verfasserin |4 aut | |
| 700 | 1 | |a Szabo, Ferenc |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Andrew H |e verfasserin |4 aut | |
| 700 | 0 | |a Australasian Leukaemia and Lymphoma Group (ALLG) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d 2011 |g 14(2024), 1 vom: 26. März, Seite 54 |w (DE-627)NLM219701628 |x 2044-5385 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:26 |g month:03 |g pages:54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41408-024-00996-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 26 |c 03 |h 54 | ||